trending Market Intelligence /marketintelligence/en/news-insights/trending/z1rFEjtMoMQ76MGsH33nlw2 content esgSubNav
In This List

ImmunoPrecise to acquire U-Protein for €6.8M

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


ImmunoPrecise to acquire U-Protein for €6.8M

ImmunoPrecise Antibodies Ltd. acquired all of U-Protein Express BV's issued and outstanding shares for €6.8 million.

ImmunoPrecise will pay €2.7 million in cash, issue €2 million of its shares and settle the remaining €2 million over a three-year period, either in cash or stock.

Martin Hessing, one of the principal shareholders of U-Protein, will join the ImmunoPrecise board.

ImmunoPrecise recently upsized a private placement to use the proceeds for the acquisition of U-Protein.